Certara Integrates Nvidia’s BioNeMo Toolkit to Accelerate AI-Driven Drug Discovery
CERT•Certara has integrated Nvidia’s BioNeMo toolkit into its AI-driven drug development platform to enhance biomolecular modeling capabilities using GPU-accelerated deep learning. The partnership provides pre-trained protein design models and scalable HPC access aimed at speeding drug candidate identification and reducing discovery timelines.
1. Collaboration Details
On July 7, 2026, Certara announced a strategic collaboration with Nvidia to embed the BioNeMo toolkit into its AI-driven drug development platform. The agreement grants Certara direct access to Nvidia’s suite of open-source, pre-trained models for protein design and molecular simulations.
2. BioNeMo Toolkit Integration
The BioNeMo toolkit comprises deep learning architectures trained on extensive biomolecular datasets, enabling predictions of protein structure, function and binding affinity. By leveraging Nvidia’s GPU-accelerated HPC infrastructure, Certara will run large-scale simulations and refine candidate molecules with higher accuracy.
3. Impact on Drug Development
By integrating GPU-accelerated compute and advanced biomolecular models, Certara expects to accelerate hypothesis testing and compound optimization cycles. The company aims to reduce experimental iterations and move promising candidates more quickly from early discovery to preclinical evaluation.
